SCHEMBL3781270

SCHEMBL3781270

Cc1ccc(N2CCNC2)cc1

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRB1 P08588 8/20 0.77
HTR3A P46098 7/20 0.48
HTR3E A5X5Y0 3/20 0.48
HTR3B O95264 3/20 0.48
HTR3D Q70Z44 3/20 0.48
HTR3C Q8WXA8 3/20 0.48
SIGMAR1 Q99720 3/20 0.48
HTR1A P08908 5/20 0.46
HTR1D P28221 2/20 0.46
HTR1B P28222 2/20 0.46
HTR7 P34969 2/20 0.46
HTR2B P41595 2/20 0.46
HTR6 P50406 2/20 0.46
HTR5A P47898 1/20 0.46
ADRB2 P07550 1/20 0.44
NCF1 P14598 1/20 0.44
PLD1 Q13393 1/20 0.44
ESRRB O95718 2/20 0.43
ESRRG P62508 2/20 0.43
KCNH2 Q12809 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9881493 0.88 ADRB1 (0.60) ADRB1HTR3AHTR3EHTR3BHTR3D
SCHEMBL81940 0.87 ADRB1 (1.00) ADRB1HTR3AHTR3EHTR3BHTR3D
SCHEMBL6645952 0.87 ADRB1 (1.00) ADRB1HTR3AHTR3EHTR3BHTR3D
Hydrochloric Acid SCHEMBL314404 0.85 ADRB1 (0.96) ADRB1HTR3AHTR3EHTR3BHTR3D
Hydrochloric Acid SCHEMBL3719334 0.85 ADRB1 (0.96) ADRB1HTR3AHTR3EHTR3BHTR3D
Water SCHEMBL27430691 0.83 ADRB1 (0.92) ADRB1HTR3AHTR3EHTR3BHTR3D
Dimethylamine SCHEMBL28750709 0.82 ADRB1 (0.88) ADRB1HTR3AHTR3EHTR3BHTR3D
SCHEMBL82301 0.80 ADRB1 (0.85) ADRB1HTR3AHTR3EHTR3BHTR3D
SCHEMBL5547864 0.79 MAOB (0.49) ADRB1HTR3AHTR3EHTR3BHTR3D
SCHEMBL7729843 0.79 ADRB1 (0.52) ADRB1HTR3AHTR3EHTR3BHTR3D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE45173-E1 Inhibitors of CYP 17 NOVARTIS AG (CH) 2014-09-30 US disclosed
US-8263635-B2 Inhibitors of CYP 17 NOVARTIS AG (CH) 2012-09-11 US disclosed
CN-101665567-B Method for controllable ring-opening polymerization of cyclic compound catalyzed by carbene derivative NANJING UNIVERSITY OF TECHNOLOGY 2011-11-23 CN disclosed
US-20100331326-A1 Inhibitors of CYP 17 NOVARTIS AG 2010-12-30 US disclosed
CN-101665567-A Method for controllable ring-opening polymerization of cyclic compound catalyzed by carbene derivative NANJING UNIVERSITY OF TECHNOLOGY 2010-03-10 CN disclosed
EP-0279681-A2 Saturated heterocyclic carboxamide derivatives YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) 1988-08-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100331326-A1 Inhibitors of CYP 17 CYP17A1, CYP21A2, CYP4A22 ADRB1 1296/4885HTR3A 710/4885HTR3E 811/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.